Radiofrequency Ablation for the Treatment of Gastric Dysplasia

Status Completed

Clinical Trial Summary

The finding of gastric dysplasia not associated with macroscopic lesions (DNAML) or the follow-up of dysplasia after endoscopic resection (DAER) is a challenging dilemma. In the last few years, radiofrequency ablation (RFA) has become a recognized tool in the treatment of dysplastic Barrett's esophagus, but its use in gastric dysplasia has not yet been studied. The investigators aim to study the efficacy, safety and tolerability of RFA in the treatment of dysplastic gastric mucosa.

Clinical Trial Description

Gastric cancer is the fourth most common cancer and the second leading cause of cancer related death worldwide. The 10-year survival of patients with this malignancy is 20% due to advanced disease at the time of diagnosis. Screening programs in countries with a high incidence of gastric neoplasia aim to detect early stage cancer, suitable for curative treatment. Well-differentiated dysplastic gastric lesions limited to the mucosa (when non-ulcerated or ulcerated and less than 3 cm) or limited to the superficial submucosa (when less than 3 cm and with no lymphatic or vascular invasion) have a negligible risk of lymph node metastasis and are suitable for endoscopic curative treatment.

Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection (ESD) have been increasingly used in this setting with promising results. However, even with these advanced techniques, en bloc and R0 resection is not possible in up to 13-15% and 16-26% of the cases, respectively. The presence of dysplasia after endoscopic resection (DAER) in the post-resection scar presents a challenging dilemma due to the technical difficulty, and associated complications, of performing subsequent EMR/ESD in fibrotic tissue. Another issue of concern is the presence of gastric dysplasia not associated with macroscopic lesions (DNAML). In such cases, a targeted endoscopic treatment is difficult and clinical management is not standardized.

Radiofrequency ablation (RFA) has been increasingly advocated for the treatment of dysplastic Barrett's esophagus (BE) and early esophageal squamous cell carcinoma (ESCC), but its use in gastric dysplasia has not yet been tested. The investigators aim to study the role of gastric RFA in the treatment of DNAML and DAER. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01523912
Study type	Interventional
Source	Hospital Sao Joao
Contact
Status	Completed
Phase	Phase 4
Start date	January 2011
Completion date	May 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00339989` - Cervical Cancer Early Endpoints and Determinants
Completed	`NCT01954836` - Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial	N/A
Not yet recruiting	`NCT03979014` - Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative The NOVEL Trial	Phase 3
Completed	`NCT02065297` - Quantitative and Functional Study of TH17 Lymphocytes in Horton's Disease (HD)
Recruiting	`NCT02049645` - The Suitability of Sniff Dog as a Tool in Screening Tumors
Recruiting	`NCT02049658` - The Sensitivity and Specificity of Sniff Dog as a Tool in Diagnosing the Suspected Tumor Patients
Completed	`NCT03415126` - A Study of ASN007 in Patients With Advanced Solid Tumors	Phase 1
Enrolling by invitation	`NCT00792649` - Comparison Between HD+ Endoscopy and Standard Videoendoscopy in Screening Colonoscopy	N/A
Recruiting	`NCT05158712` - Genetic Factors and Pheochromocytomas in Neoplasia Type 2
Completed	`NCT01962103` - Study to Find a Safe Dose and Show Early Clinical Activity of Weekly Nab-paclitaxel in Pediatric Patients With Recurrent/ Refractory Solid Tumors	Phase 1/Phase 2
Terminated	`NCT01456143` - Optical Imaging of Head and Neck Cancer	N/A
Recruiting	`NCT04341181` - ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling	Phase 2
Recruiting	`NCT02925234` - The Drug Rediscovery Protocol (DRUP Trial)	Phase 2

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.